Published in Cancer Weekly, May 29th, 2007
In the open-label, randomized dose-finding Phase IIb-trial adult patients with recurrent or refractory high-grade glioma were treated either with one of two doses of the TGF-beta2 inhibitor AP 12009 - applied by convection-enhanced delivery - or chemotherapy (temozolomide or PCV) as a control. Survival data in the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.